NASDAQ:CFRX - ContraFect Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ContraFect Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.12 +0.08 (+7.69 %) (As of 01/22/2020 06:00 AM ET) Add Compare Today's Range$1.07Now: $1.12▼$1.1550-Day Range$0.29MA: $0.65▼$1.2352-Week Range$0.27Now: $1.12▼$1.34Volume1.68 million shsAverage Volume2.70 million shsMarket Capitalization$171.72 millionP/E Ratio28.01Dividend YieldN/ABeta0.51 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CFRX Previous Symbol CUSIPN/A CIK1478069 Webhttp://www.contrafect.com/ Phone914-207-2300Debt Debt-to-Equity Ratio0.79 Current Ratio1.68 Quick Ratio1.68Price-To-Earnings Trailing P/E Ratio28.01 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.07 per share Price / Book16.00Profitability EPS (Most Recent Fiscal Year)($0.37) Net Income$-37,680,000.00 Net MarginsN/A Return on Equity-79.48% Return on Assets-28.62%Miscellaneous Employees20 Outstanding Shares153,320,000Market Cap$171.72 million Next Earnings Date3/12/2020 (Estimated) OptionableNot Optionable Receive CFRX News and Ratings via Email Sign-up to receive the latest news and ratings for CFRX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CFRX Rates by TradingView ContraFect (NASDAQ:CFRX) Frequently Asked Questions What is ContraFect's stock symbol? ContraFect trades on the NASDAQ under the ticker symbol "CFRX." How were ContraFect's earnings last quarter? ContraFect Corp (NASDAQ:CFRX) posted its quarterly earnings results on Tuesday, November, 12th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01. View ContraFect's Earnings History. When is ContraFect's next earnings date? ContraFect is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for ContraFect. What price target have analysts set for CFRX? 2 analysts have issued twelve-month price objectives for ContraFect's shares. Their forecasts range from $1.50 to $2.00. On average, they anticipate ContraFect's stock price to reach $1.75 in the next twelve months. This suggests a possible upside of 56.3% from the stock's current price. View Analyst Price Targets for ContraFect. What is the consensus analysts' recommendation for ContraFect? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ContraFect. Has ContraFect been receiving favorable news coverage? Media headlines about CFRX stock have trended somewhat negative on Wednesday, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ContraFect earned a daily sentiment score of -1.5 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for ContraFect. Are investors shorting ContraFect? ContraFect saw a increase in short interest in the month of December. As of December 13th, there was short interest totalling 341,900 shares, an increase of 338.3% from the November 28th total of 78,000 shares. Based on an average trading volume of 714,900 shares, the short-interest ratio is currently 0.5 days. Currently, 0.5% of the company's shares are short sold. View ContraFect's Current Options Chain. Who are some of ContraFect's key competitors? Some companies that are related to ContraFect include TherapeuticsMD (TXMD), AC Immune (ACIU), Morphic (MORF), Kadmon (KDMN), Kura Oncology (KURA), Akero Therapeutics (AKRO), Crinetics Pharmaceuticals (CRNX), Prothena (PRTA), MacroGenics (MGNX), Magenta Therapeutics (MGTA), Neoleukin Therapeutics (NLTX), Clovis Oncology (CLVS), BioDelivery Sciences International (BDSI), Viking Therapeutics (VKTX) and OrganiGram (OGI). What other stocks do shareholders of ContraFect own? Based on aggregate information from My MarketBeat watchlists, some companies that other ContraFect investors own include SCYNEXIS (SCYX), Catalyst Pharmaceuticals (CPRX), Antares Pharma (ATRS), Edge Therapeutics (EDGE), Nabriva Therapeutics (NBRV), Synergy Pharmaceuticals (SGYP), Cara Therapeutics (CARA), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO) and Portola Pharmaceuticals (PTLA). Who are ContraFect's key executives? ContraFect's management team includes the folowing people: Dr. Steven C. Gilman, Exec. Chairman, CEO & Pres (Age 66)Mr. Michael Messinger CPA, CPA, CFO & Chief Accounting Officer (Age 44)Ms. Nancy Dong, VP of Fin. & Admin. (Age 54)Ms. Natalie Bogdanos J.D., Gen. Counsel, Corp. Sec. & Data Protection Officer (Age 50)Dr. Cara Cassino, Chief Medical Officer and Exec. VP of R&D (Age 57) How do I buy shares of ContraFect? Shares of CFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is ContraFect's stock price today? One share of CFRX stock can currently be purchased for approximately $1.12. How big of a company is ContraFect? ContraFect has a market capitalization of $171.72 million. The biotechnology company earns $-37,680,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. ContraFect employs 20 workers across the globe.View Additional Information About ContraFect. What is ContraFect's official website? The official website for ContraFect is http://www.contrafect.com/. How can I contact ContraFect? ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The biotechnology company can be reached via phone at 914-207-2300 or via email at [email protected] MarketBeat Community Rating for ContraFect (NASDAQ CFRX)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 199 (Vote Outperform)Underperform Votes: 183 (Vote Underperform)Total Votes: 382MarketBeat's community ratings are surveys of what our community members think about ContraFect and other stocks. Vote "Outperform" if you believe CFRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CFRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/22/2020 by MarketBeat.com StaffFeatured Article: How does quantitative easing work?
